PROFHILO H+L (1x2ml) IBSA

PROFHILO H+L (1x2ml) IBSA

STRICT MEDICAL USE IN MEDICAL OFFICES. Authorized status. Medical device CLASS III. European CE marking.

PROFHILO SPECIFICITIES

• OBJECTIVE OF TREATMENT / INDICATION: BIOREMODELLING OF CUTANEOUS LAXITY.
• AREA: FACE. NECK. LOW-CUT.
• HA CONCENTRATION: 64 MG FOR 2 ML.
• HYDRO ACTION: 5/5
• LIFT ACTION: 3/5
• PACKAGING: 2 ML SYRINGE.
• NEEDLE: 29G THIN WALL x 13mm.
• PROTOCOL: 2 SESSIONS. Evaluation 2 months after the last treatment. If necessary repeat the treatment.
• SUGGESTED TECHNIQUE: BAP.
• INJECTION LAYER: DEEP DERMIS.

DESCRIPTION

IBSA's Hyaluronic Acid is an ultrapure hyaluronic acid, produced by a patented bio-fermentation process of Streptococcus Zooepidemicus, rated worldwide as "Top Quality" in terms of purity, safety and quality. high resistance to thermal production processes. The formulation of HA with different molecular weights contained in PROFHILO is based on a concept of Hydrolift Action. This innovative approach aims to counter the physiological reduction of HA in the skin, to restore hydration, elasticity and tone of the skin, by combining, in a synergistic way, deep hydration with the mechanical action of lifting the skin. skin. It is the first stabilized hyaluronic acid (HA) product that is manufactured without the use of chemical cross-linking agents (BDDE).

INDICATION PROFHILO

• The injectable medical device PROFHILO intervenes in the physiological process of skin aging in the process of repairing dermal tissue in the event of scars resulting from superficial skin trauma.
• PROFHILO is used for skin contouring and the treatment of sagging skin, not just for filler lines and wrinkles.
• With one of the highest concentrations of HA on the market (64mg/2ml), it not only stimulates and hydrates the skin, but also reshapes aging and sagging tissue.

INJECTION AREAS

• PROFHILO is indicated for the treatment of the face and body to redefine contours and reshape laxity.
• However, it is particularly indicated for the treatment of malar-zygomatic, submalar, brachial, abdominal areas and areas affected by sagging skin.

DURABILITY

As a stabilized product, Profhilo lasts in the skin for approximately 28 days. During this period, the stimulation of 4 different types of collagen and elastin takes place by a slow release of HA. Stimulation results in significant tissue improvement. Therefore, we cannot say that Profhilo is a skin enhancer, as it also has a significant tightening/lifting effect on the tissue. It is considered safe, effective and "a real breakthrough" in anti-aging treatment. Hyaluronic acid is totally broken down in the skin and leaves no traces.

RESULTS

Improved fabric quality. Skin remodeling. Treatment of sagging skin. Restoration of skin firmness.

COMPOSITION

Stable hybrid cooperative complexes of low and high molecular weight hyaluronic acid. 3.2% – 32 mg (H-HA) + 32 mg (L-HA)/2 ml Hyaluronic acid sodium salt.

PROFHILO:

• 3.2% - 16 mg (H-HA) + 16 mg (L-HA)/1 ml hyaluronic acid sodium salt.
• 3.2% - 32mg (H-HA) + 32mg (L-HA)/2ml hyaluronic acid sodium salt.
• Medical device for intradermal use.
• Sterile - Single use.

PRESENTATION

• Pre-filled syringe of 2 ml.
• 2 TERUMO needles type 29G x ½ (29Gx13).
• A product leaflet. 
• 2 product traceability stickers.

NAHYCO TECHNOLOGY

NAHYCO Hybrid Technology combines innovation and comprehensive safety with the production of cooperative stabilized hybrid hyaluronic acid complexes formed using a patented thermal process. Thanks to this new technology, it was possible to combine 32 mg of low molecular weight HA (L-HA: 80 to 100 KDa) and 32 mg of HA HA (H-HA: 1100 to 1400 KDa) of high molecular weight while maintaining comprehensive management. A total concentration of 64 mg is produced, which has never been achieved before precisely due to technological limitations. This process does not involve the use of chemical cross-linking agents, such as BDDE (1,4-butanediol diglycidyl ether), and the end product, PROFHILO, is pure hyaluronic acid.

IBSA Italia

PROFHILO is manufactured by IBSA Farmaceutici Italia in an FDA approved site in Italy and distributed in the UK and Ireland by HA-Derma Ltd.